Clinical development plan: β‐Carotene and other carotenoids

Journal of Cellular Biochemistry

Volumn 56, Issue 20 S, 1994, Pages 110-140

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CAROTENE; CAROTENOID;

ANIMAL; ARTICLE; CLINICAL TRIAL; COLON TUMOR; DRUG APPROVAL; HAMSTER; HUMAN; METHODOLOGY; MOUSE; RAT; STANDARD;

ANIMAL; ANTINEOPLASTIC AGENTS; BETA CAROTENE; CAROTENOIDS; CLINICAL TRIALS; COLONIC NEOPLASMS; DRUG APPROVAL; HAMSTERS; HUMAN; MICE; RATS;

EID: 0028685878     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240560910     Document Type: Article

References (190)

1. The safety of β‐carotene.
2. The toxicity of beta‐carotene.
3. Dietary inhibitors of mutagenesis and carcinogenesis.
4. Dietary vitamin A and risk of cancer in the Western Electric study.
5. Serum vitamin levels and the risk of cancer of specific sites in men of Japanese ancestry in Hawaii.
6. Carotenoid intake, vegetables, and the risk of lung cancer among white men in New Jersey.
7. Carotenoids, cancer, and clinical trials.
8. Relationship between carotenoids and cancer. The Multiple Risk Factor Intervention Trial (MRFIT) study.
9. Cancer, vitamins, and plasma lipids: Prospective Basel study.
10. Serum beta‐carotene, vitamins A and E, selenium, and the risk of lung cancer.
11. Serum levels of β‐carotene, vitamin A, and zinc in male lung cancer cases and controls.
12. Dietary beta‐carotene and lung cancer risk in U. S. nonsmokers.
13. Dietary vitamin A and the risk of invasive cervical cancer.
14. Retinoids and the prevention of cervical dysplasias.
15. Plasma levels of antioxidant β‐carotene and α‐tocopherol in uterine cervix dysplasias and cancer.
16. Serum vitamins A and E and carotene in patients with gynecologic cancer.
17. Esophageal cancer among black men in Washington, D. C. II. Role of nutrition.
18. Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China.
19. Carotene intake and the risk of laryngeal cancer in coastal Texas.
20. Can dietary beta‐carotene materially reduce human cancer rates?
21. Plasma vitamin ‘A’ and carotene levels in squamous cell carcinoma of oral cavity and oro‐pharynx.
22. Oral and pharyngeal cancer, diet, smoking, alcohol, and serum vitamin A and β‐carotene levels: A case‐control study in men.
23. Nutritional risk factors and ovarian cancer.
24. Modelling the relative risk of esophageal cancer in a case‐control study.
25. Beta‐carotene, vitamin A and prostatic cancer.
26. Serum retinol, beta‐carotene, vitamin E, and selenium as related to subsequent cancer of specific sites.
27. β‐Carotene and cancer prevention: The Basel study.
28. A population‐based case‐control study of diet and breast cancer in Australia.
29. Dietary factors and risk of breast cancer: Combined analysis of 12 case‐control studies.
30. Dietary and serum carotenoids and cervical intraepithelial neoplasia.
31. Serologic precursors of cancer: Serum micronutrients and the subsequent risk of pancreatic cancer.
32. Vegetable consumption and lung cancer risk: A population‐based case‐control study in Hawaii.
33. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: A reevaluation of the effect of dietary beta‐carotene.
34. Serum micronutrients and the subsequent risk of cervical cancer in a population‐based nested case‐control study.
35. Evaluation of vitamin A toxicity.
36. Biological actions of carotenoids.
37. β‐Carotene: Functions
38. Vitamin A
39. Carotenemia.
40. Modulation of carcinogenesis by vitamin A and its analogs (retinoids)
41. Mechanism of the in vitro antimutagenic action of retinol.
42. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication.
43. Action of some retinol derivatives and their provitamins on microsome‐catalyzed formation of benzo[ a]‐pyrene‐DNA adduct.
44. Inhibition of arachidonic acid oxidation by β‐carotene, retinol and α‐tocopherol.
45. β‐Carotene: An unusual type of lipid antoxidant.
46. Lycopene as the most efficient biological carotenoid singlet oxygen quencher.
47. Free radical scavenging of lutein in vitro.
48. Retinoids and carotenoids are peroxyl radical scavengers
49. Radical intermediates involved in the bleaching of the carotenoid crocin. Hydroxyl radicals, superoxide anions and hydrated electrons.
50. Protection by β‐carotene and related compounds against oxygen‐mediated cytotoxicity and genotoxicity: Implications for carcinogenesis and anticarcinogenesis.
51. Cellular bound beta‐carotene quenches singlet oxygen in man.
52. Immunomodulating actions of carotenoids: Enhancement of in vivo and in vitro antibody production to T‐dependent antigens.
53. Effect of β‐carotene on lymphocyte subpopulations in elderly humans: Evidence for a doseresponse relationship.
54. β‐Carotene and canthaxanthin inhibit chemically‐ and physically‐induced neoplastic transformation in 10T 1/2 cells.
55. Diverse carotenoids protect against chemically induced neoplastic transformation.
56. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T 1/2 cells: Relationship to their cancer chemopreventive action.
57. β‐Carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture.
58. Effects of carotenoids on cells.
59. Carotenoids slow the growth of small cell lung cancer cells.
60. β‐Carotene inhibits rectal mucosal ornithine decarboxylase activity in colon cancer patients.
61. Dimethylbenz( a)anthracene (DMBA)‐induced guanylate cyclase (GC) activity in rat uteri: Inhibition by β‐carotene (BC).
62. Beta‐carotene accumulation in serum and skin.
63. Beta‐carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases.
64. Modifying effect of dietary selenium and β‐carotene on benzo( a)pyrene induced respiratory tract tumors in hamsters.
65. Inhibition of diethylnitrosamine‐induced lung carcinogenesis by retinoids.
66. The effects of β‐carotene on BP‐induced respiratory tract tumors in hamsters.
67. Subchronic (106‐day) toxicology and nutrition studies with vitamin A and β‐carotene in Syrian hamsters.
68. Plasma concentrations of carotenoids after large doses of β‐carotene.
69. Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination.
70. Potent preventive action of α‐carotene against carcinogenesis: Spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by α‐carotene than by β‐carotene.
71. Inhibition of experimental oral carcinogenesis by topical beta‐carotene.
72. Beta‐carotene effects on experimental oral carcinogenesis in the hamster.
73. Prevention and inhibition of oral cancer in the hamster buccal pouch model associated with carotenoid imune enhancement.
74. Protective single/combined treatment with betel leaf and turmeric against methyl(acetoxymethyl)nitrosamine‐induced hamster oral carcinogenesis.
75. The effect of different levels of dietary β‐carotene on DMBA‐induced salivary gland tumors.
76. Intermediate biomarkers of precancer and their application in chemoprevention.
77. Modulatory effects of snuff, retinoic acid, and β‐carotene on DMBA‐induced hamster cheek pouch carcinogenesis in relation to keratin expression.
78. Dietary carotenoids block photocarcinogenic enhancement by benzo( a)pyrene and inhibit its carcinogenesis in the dark.
79. Antitumor activity of β‐carotene, canthaxanthine and phytoene.
80. Carotenoid dose level and protection against UV‐B induced skin tumors.
81. Prevention of the benzo( a)pyrene photo‐carcinogenic effect by β‐carotene and canthaxanthine. Preliminary study.
82. Chemoprevention of skin cancer by carotenoids.
83. Effects of β‐carotene on chemically‐induced skin tumors in HRA/Skh hairless mice.
84. Carotenoids affect development of UV‐B induced skin cancer.
85. Anticarcinogensis activity of natural carotenes.
86. The effect of crocetin on skin papillomas and Rous sarcoma.
87. Effect of crocetin on experimental skin tumors in hairless mice.
88. Carotenoid pigment administration and delay in development of UV‐B‐induced tumors.
89. Dimethylbenz( a)anthracene (DMBA)‐induced tumors: Prevention by supplemental β‐carotene (BC).
90. 7,12‐Dimethylbenz( a)anthracene (DMBA) carcinogenicity: Moderation by supplemental beta‐carotene (B‐Car) and vitamin A (Vit A).
91. Inhibition by β‐carotene‐rich algae Dunaliella of spontaneous mammary tumourigenesis in mice.
92. Effect of canthaxanthin on chemically induced mammary carcinogenesis.
93. Protective effect of β‐carotene against colon tumors in mice.
94. Antioxidants vs. carotenoids. Inhibitors or promoters of experimental colorectal cancers.
95. 1‐induced liver tumours by antioxidants with increased activity of microsomal enzymes.
96. Inhibitory effects of β‐carotene on preneoplastic lesions induced in Wistar rats by the resistant hepatocyte model.
97. Inhibitory effect of β‐carotene on chronic 2‐acetylamino‐fluorene induced hepatocarcinogenesis in rat: Reflection in hepatic drug metabolism.
98. 1 in rats.
99. 1‐induced hepatotoxic lesions by crocetin (a natural carotenoid).
100. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin.
101. Inhibitory effects of micronutrients on pancreatic carcinogenesis in azaserine‐treated rats.
102. Inhibition of dietary fat promoted development of (pre)neoplastic lesions in exocrine pancreas of rats and hamsters by supplemental selenium and β‐carotene.
103. Hypervitaminosis A and harmlessness of large doses of carotene.
104. Chronic toxicity studies of β‐carotene.
105. Lack of genotoxicity with beta‐carotene.
106. Experimental studies on the teratogenic effects of vitamin A: I. Effects of β‐carotene.
107. 14C]β‐carotene and the presence of other carotenoids in rats and monkeys.
108. Kinetic characteristics of β‐carotene uptake and depletion in rat tissue.
109. 14C]lycopene in rats and monkeys.
110. Concentrations of selected carotenoids and vitamin A in human liver, kidney and lung tissue.
111. Retinol, α‐tocopherol, lutein/zeaxanthin, β‐carotenthin, lycopene, α‐carotene, trans‐β‐carotene, and four retinyl esters in serum determined simutaneously by reversed‐phase HPLC with multi‐wavelength detection.
112. Carotenodermia in men with elevated carotenoid intake from food and β‐carotene suplements.
113. Carotenemia.
114. Carotene and retinol efficacy trial: Lung cancer chemoprevention trial in heavy cigarette smokers and asbestos‐exposed workers.
115. The carotene and retinol efficacy trial (CARET) to prevent lung cancer in high‐risk populations: Pilot study with asbestos‐exposed workers.
116. The carotene and retinol efficacy trial (CARET) to prevent lung cancer in high‐risk populations: Pilot study with cigarette smokers.
117. Bioavailability of β‐carotene in humans.
118. Rapid serum carotene loading with high‐dose β‐carotene: Clinical implications.
119. Canthaxanthin retinopathy. Follow‐up of over 6 years.
120. Carotenoids in the human macula and whole retina.
121. Biological control of primate macular pigment. Biochemical and densitometric studies.
122. Stereochemistry of the human macular carotenoids.
123. Biological availability of fat‐soluble vitamins: Vitamin A and carotene.
124. Provitamin A function of carotenoids: The conversion of β‐carotene into vitamin A.
125. 13C‐β‐carotene and high precision isotope ratio mass spectrometry.
126. Serum reference values for lutein and zeaxanthin using a rapid separation technique.
127. A pilot study on the use of plasma carotenoids and ascorbic acid as markers of compliance to a high fruit and vegetable dietary intervention.
128. Carotenoids
129. Plasma betacarotene levels—kinetic patterns during administration of various doses of beta‐carotene.
130. Studies on the absorption of beta‐carotene and the distribution of total carotenoid in human serum lipoproteins after oral administration.
131. The intestinal absorption and metabolism of vitamin A and β‐carotene in man.
132. Plasma carotenoids in normal men after a single ingestion of vegetables or purified β‐carotene.
133. Normal serum response to oral beta‐carotene in humans.
134. Serum level changes after administration of a pharmacologic dose of β‐carotene.
135. Determinants of increase in plasma concentration of β‐carotene after chronic oral supplementation.
136. cis‐trans Isomers of lycopene and β‐carotene in human serum and tissues.
137. Carotenoid composition, concentrations, and relationships in various human organs.
138. Uptake of lycopene and its geometrical isomers is greater from heat‐processed than from unprocessed tomato juice in humans.
139. Separation, identification, and quantification of carotenoids in fruits, vegetables and human plasma by high performance liquid chromatography.
140. Carotenoids in human blood and tissues.
141. The effect of vitamin E and beta‐carotene on the incidence of lung cancer and other cancers in male smokers.
142. Folate, carotene, and smoking.
143. Baseline data analysis of serum beta‐carotene in a randomized clinical trial: The Tyler Cancer Prevention Program.
144. Characteristics of subjects with high and low serum beta‐carotene (SBC): Implications for lung cancer risk.
145. The β‐Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos‐exposed workers.
146. CARET, the β‐carotene and retinol efficacy trial to prevent lung cancer in asbestos‐exposed workers and in smokers.
147. Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET).
148. Chemoprevention of lung cancer: Problems and progress.
149. Beta‐carotene supplementation in smokers reduces the frequency of micronuclei in sputum.
150. Consumption of salted fish and other risk factors for nasopharyngeal carcinoma (NPC) in Tianjin, a low‐risk region for NPC in the People's Republic of China.
151. Reduction in plasma or skin alphatocopherol concentration with longterm oral administration of beta‐carotene in humans and mice.
152. Potential role of beta‐carotene and antioxidant vitamins in the prevention of oral cancer.
153. Beta‐carotene (BC) is an effective, non‐toxic agent for the treatment of premalignant lesions of the oral cavity.
154. Response of oral leukoplakia to beta‐carotene.
155. Beta‐carotene in oral leukoplakia (meeting abstract).
156. β‐Carotene and vitamin E in oral cancer prevention.
157. Evaluation of serum and tissue levels of β‐carotene.
158. Comparison of low‐dose isotretinoin with beta carotene to prevent oral carcinogenesis.
159. Management of oral mucosal dysplasia with β‐carotene retinoic acid: A pilot cross‐over study.
160. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis.
161. Beta‐carotene supplementation in the treatment of oral lesions.
162. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer.
163. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease‐specific mortality in the general population.
164. Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China.
165. Reduction with vitamin A and β‐carotene administration of proportion of micronucleated buccal mucosal cells in Asian betel nut and tobacco chewers.
166. Use of the micronucleus test to monitor the effect of vitamin A, beta‐carotene and canthaxanthin on the buccal mucosa of betel nut/tobacco chewers.
167. A pilot beta‐carotene intervention trial with Inuits using smokeless tobacco.
168. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta‐carotene and with beta‐carotene plus vitamin A.
169. The Skin Cancer Prevention Study: Design of a clinical trial of β‐carotene among persons at high risk for non‐melanoma skin cancer.
170. A clinical trial of β‐carotene to prevent basal‐cell and squamous‐cell cancers of the skin.
171. A clinical trial of antioxidant vitamins to prevent colorectal adenoma.
172. Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps.
173. Growth of colorectal polyps: Design of a prospective, randomized, placebo‐controlled intervention study in patients with colorectal polyps.
174. Premalignant lesions: Role of antioxidant vitamins and β‐carotene in risk reduction and prevention of malignant transformation.
175. β‐Carotene levels in exfoliated cervicovaginal epithelial cells in cervical intraepithelial neoplasia and cervical cancer.
176. The effect of beta‐carotene on the regression and progression of cervical dysplasia: A clinical experiment.
177. A randomized trial of aspirin and β‐carotene among U. S. physicians.
178. The 2×2 factorial design: Its application to a randomized trial of aspirin and carotene in U. S. physicians.
179. Baseline characteristics of participants in the Physicians' Health Study: A randomized trial of aspirin and β‐carotene in U. S. physicians.
180. Low‐dose aspirin and incidence of colorectal tumors in a randomized clinical trial.
181. Isolation and structural elucidation of the geometrical isomers of lutein and zeaxanthin in extracts from human plasma.
182. Separation and identification of carotenoids and their oxidation products in the extracts of human plasma.